THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

31 March 2026

Solvonis Therapeutics plc
("Solvonis" or the "Company")

Granted U.S. Patent from PTSD Discovery Programme

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces it has been granted a U.S. patent by the United States Patent and Trademark Office ("USPTO") covering a monoamine modulator compound series arising from its proprietary post-traumatic stress disorder ("PTSD") discovery programme.

The patent, U.S. Patent No. 12,590,077, covers a monoamine modulator compound series designed to modulate serotonin, dopamine and noradrenaline transporter systems (SERT, DAT and NET).

PTSD is a large and underserved market affecting more than 20 million people across the UK, U.S. and major European markets, with limited approved pharmacological treatment options. Recent strategic activity in the sector, including Otsuka Pharmaceutical Co., Ltd.'s ("Otsuka") agreement to acquire Transcend Therapeutics for total potential consideration of US$1.225 billion, highlights growing strategic and commercial interest in next-generation PTSD treatments.

As a composition-of-matter patent, it protects the underlying compounds themselves rather than only how they are used or manufactured. This is generally regarded as the strongest and most commercially valuable form of patent protection in drug development.

The granted patent builds on the Company's previously announced USPTO patent allowance in January 2026 in relation to compounds arising from its PTSD discovery programme. Since that milestone, Solvonis has also selected SVN-114 as the lead candidate from the programme.

Importantly, this patent is part of a broader protected chemistry estate being built around the Company's PTSD discovery programme, providing additional optionality for future optimisation, lifecycle management and potential follow-on development.

Anthony Tennyson, CEO of Solvonis Therapeutics plc, commented: "This patent strengthens the long-term value of our PTSD programme in an area of clear unmet need and rising strategic and commercial interest, highlighted by Otsuka's agreement to acquire Transcend Therapeutics for total potential consideration of US$1.225 billion. Strong intellectual property is central to value creation in biotech, and securing composition-of-matter protection at the level of the underlying compounds materially strengthens our position. Importantly, it supports a broader chemistry platform beyond a single asset, giving us greater flexibility as we advance SVN-114 and continue to expand our CNS pipeline."

Professor David Nutt, Chief Scientific Officer of Solvonis Therapeutics plc, added: "This patent reflects one of the chemically distinct series arising from our monoamine modulation research. Exploring multiple series is a deliberate strategy because it provides alternative compounds and differentiated profiles to support future optimisation and development."

Enquiries:

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.

The Company's lead programmes target Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company's PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain signalling systems associated with emotional processing and social behaviour.

In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across addiction and psychiatry.

With a capital-efficient development model and a focus on partnering opportunities, Solvonis aims to deliver sustained value through innovation in CNS therapeutics.

solvonis.com | LinkedIn | X (Twitter)